XORTX Therapeutics Inc.
XORTX Therapeutics Inc. is a pharmaceutical company with two clinically advanced products in development – XRx-008 for Autosomal Dominant Polycystic Kidney Disease (ADPKD), XRx-101 for Coronavirus / COVID-19 infection and XRx-225 is a pre-clinical stage program for Type 2 Diabetic Nephropathy (T2DN). XORTX is working to advance its clinical development stage products that target aberrant purine metabolism and xanthine oxidase to decrease or inhibit production of uric acid. At XORTX Therapeutics, we are dedicated to developing medications to improve the quality of life and future health of patients. Additional information on XORTX Therapeutics is available at www.xortx.com.
XORTX Therapeutics Inc. (XRX)
Le 21 septembre/September 2021
XORTX Therapeutics Inc. has announced a consolidation of its issued and outstanding common shares on the basis of 1 post-consolidation common share for every 11.74 pre-consolidation common shares.
As a result, the outstanding shares of the company will be reduced to approximately 9,443,508 common shares.
The name and symbol will not change.